Literature DB >> 2524005

5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue.

J M Barnes1, N M Barnes, B Costall, R J Naylor, M B Tyers.   

Abstract

The release of cerebral acetylcholine from terminals in the cerebral cortex has been shown to be regulated by 5-hydroxytryptamine (5-HT) but it is not known which subtype of the 5-HT receptor is involved. 5-HT receptor agonists increase acetylcholine levels in vivo, indicating a reduced turnover, and reduce release of acetylcholine from striatal slices in vitro. Depleting 5-HT by inhibiting synthesis or by destroying the neurons containing 5-HT potentiates acetylcholine release, and increases acetylcholine turnover in the cerebral cortex and hippocampus. Selective antagonists for the 5-HT3 receptor subtypes which seem to have effects on mood and activity may exert their effect through the regulation of acetylcholine release in the cortex and limbic system. Radioligand binding studies show a high density of 5-HT3 receptors in the cholinergic-rich entorhinal cortex and we provide evidence that a reduction in cortical cholinergic function can be effected in vitro by 5-HT3 receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524005     DOI: 10.1038/338762a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  38 in total

1.  Activation and desensitization of the 5-HT3 receptor in a rat glioma x mouse neuroblastoma hybrid cell.

Authors:  J L Yakel; X M Shao; M B Jackson
Journal:  J Physiol       Date:  1991-05       Impact factor: 5.182

2.  Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methysergide or alaproclate.

Authors:  P Riekkinen; J Sirviö; P Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 3.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Serotonergic modulation of Neural activities in the entorhinal cortex.

Authors:  Saobo Lei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

5.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons.

Authors:  T J Feuerstein; O Gleichauf; G B Landwehrmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

7.  The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

Authors:  I Artaiz; G Romero; A Zazpe; A Monge; J M Calderó; J Roca; B Lasheras; J Del Río
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

8.  Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.

Authors:  M Diez-Ariza; C Redondo; M García-Alloza; B Lasheras; J Del Río; M J Ramírez
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

9.  Independent effects of cholinergic and serotonergic lesions on acetylcholine and serotonin release in the neocortex of the rat.

Authors:  A J Dekker; L J Thal
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

10.  Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

Authors:  I K Wright; M Heaton; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.